Fig. 3

GPX4 knockdown reduces TNBC metastatic progression and obesity-related tumor burden. (A) Relative protein expression of GPX4 in shScram and shGPX4 metM-Wnt^lung cells (n = 5–6/group). (B) Percent survival of metM-Wnt^lung shGPX4 and shScramble cells treated with 500µM H₂O₂ combined with 5µM ferrostatin-1 for 24 h, relative to a DMSO-treated control for each condition (n = 3/group). (C and D) Murine lung weights (C) and pulmonary tumor nodule counts (D) 3 weeks post-injection via lateral tail vein with 10⁶ metM-Wnt^lung shGPX4 or shScramble cells pre-treated for 48 h with 5µM ferrostatin-1 or a DMSO control (n = 5/group). (E-G) Experimental timeline (E) of metM-Wnt^lung shGPX4 or shScramble cells injected into C57BL6/NCrl mice after 20 weeks on either a 60 kcal% high-fat diet (DIO) or 10 kcal% fat control diet (con). Body weights (F) and tumor weights (G) of mice were taken at study endpoint (n = 10–12/group). Statistical significance determined by Kruskal-Wallis test with Dunn’s multiple comparison test (A, B); one-way ANOVA with Tukey’s multiple comparisons test (C, D); or two-way ANOVA with Tukey’s multiple comparisons test (F, G). (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001)